Research Analysts’ ratings reiterations for Friday, January 17th: Acorda Therapeutics (NASDAQ:ACOR) had its neutral rating reissued by analysts at Zacks. Zacks currently has a $32.00 target price on the stock. Zacks’ analyst wrote, “Acorda announced preliminary unaudited Ampyra sales information in January and said that Ampyra unaudited sales were $84 million and $302 million, respectively, […]
Research Analysts’ Ratings Reiterations for January, 17th (ACOR, BBY, C, CHKP, CLR, CMS, CTSO, CUZ, EZJ, FAST) is a post from: Zolmax
The post Research Analysts’ Ratings Reiterations for January, 17th (ACOR, BBY, C, CHKP, CLR, CMS, CTSO, CUZ, EZJ, FAST) appeared first on Zolmax.
